Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Chinese Patent Office
US Army
Daiichi Sankyo

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021305

« Back to Dashboard

NDA 021305 describes HICON, which is a drug marketed by Jubilant Draximage and is included in one NDA. It is available from one supplier. Additional details are available on the HICON profile page.

The generic ingredient in HICON is sodium iodide i-131. There are one thousand four hundred and fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sodium iodide i-131 profile page.
Summary for 021305
Applicant:Jubilant Draximage
Ingredient:sodium iodide i-131
Formulation / Manufacturing:see details
Pharmacology for NDA: 021305
Mechanism of ActionRadiopharmaceutical Activity
Suppliers and Packaging for NDA: 021305
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SODIUM IODIDE I 131 sodium iodide i-131 CAPSULE;ORAL 021305 NDA Jubilant DraxImage Inc. 65174-461 65174-461-05 5 CAPSULE in 1 VIAL (65174-461-05)
SODIUM IODIDE I 131 sodium iodide i-131 CAPSULE;ORAL 021305 NDA Jubilant DraxImage Inc. 65174-880 65174-880-00 1 VIAL in 1 KIT (65174-880-00) > 1 mL in 1 VIAL

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;ORALStrength1-250mCi/0.25ML
Approval Date:Jan 24, 2003TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;ORALStrength1-500mCi/0.5ML
Approval Date:Jan 24, 2003TE:RLD:No

Profile for product number 004

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength2-200mCi
Approval Date:Nov 18, 2004TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Federal Trade Commission
Express Scripts
Queensland Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.